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planning CT and CBCT were matched on bony structures after 
automatic semi-rigid fusion alongside the 3 axis : xbone, ybone, zbone, 2) 
planning CT and CBCT were matched on the prostate with respect to 
intra-prostatic markers: xsoft, ysoft, zsoft. The position of the prostate 
within the pelvis for each pre- and post-treatment study points was 
defined as xpros= (xbone – xsoft), ypros= (ybone – ysoft) and zpros= (zbone – zsoft).  
Rectum and bladder were outlined on each CBCT with the aim to 
assess changes in rectal or vesical repletion during each fraction. 
Organ distension was assessed by measuring the average rectal cross-
sectional area (rCSA; defined as the rectal volume divided by length), 
and the area of the bladder when evaluated 2.5cm above the prostate 
base (A-blad) on pre- and post-treatment CBCT. 
Results: Two hundred and ninety four CBCT were reviewed for this 
analysis. The average fraction duration was shorter with IMAT than 
with IMRT (4'49'', vs. 11'00'', p< 0.001). During fractions of IMRT the 
prostate showed statistically significant shifts in the longitudinal (p= 
0,049) and lateral (p=0,013) axis while it was not statistically 
significant during fractions of IMAT. Intra-fraction rCSA increased 
neither during IMAT nor IMRT whereas A-blad increased only during 
fractions of IMRT but with no correlation with prostate displacements. 
Conclusions: The prostate moves within the pelvis during an IMRT 
course which could lead to a greater daily geographic miss when 
compared to the IMAT technique.  
 
PD-0131   
To predict nodal status using Artificial Intelligence approaches in 
prostate cancer: beyond the Roach formula? 
B. De Bari1, M. Vallati2, R. Gatta1, M. Buglione1, G. Girelli3, F. Munoz4, 
I. Meattini5, E. Cagna6, L. Pegurri1, S.M. Magrini1 
1Spedali Civili di Brescia - University of Brescia, Radiation Oncology 
Department - Istituto del Radio, Brescia, Italy  
2University of Huddersfield, School of Computing and Engineering, 
Huddersfield, United Kingdom  
3Ivrea Hospital, Radiotherapy Department, Ivrea, Italy  
4University of Turin, Radiotherapy Department, Turin, Italy  
5University of Florence, Radiotherapy Department, Florence, Italy  
6Como Hospital, Radiotherapy Department, Como, Italy  
 
Purpose/Objective: To present an innovative approach based on the 
methods of Artificial Intelligence (AI) to better predict N status in 
prostate cancer patients (pts), integrating some important clinical and 
therapeutic parameters (Gleason Score/sum, age, initial PSA, 
neoadjuvant or neoadjuvant/ concomitant hormonal therapy vs no 
hormonal therapy), known before radiotherapy (RT).  
Materials and Methods: A total of 1808 pts from a National Italian 
multicentric database was analyzed. Following the D’Amico criteria, 
we found 317 'low risk', 577 'intermediate risk' and 914'high risk' pts. 
with a known N status at diagnosis. N+pts were defined as those with 
a positive contrast enhanced pelvic MRI and/or CT scan; those showing 
a nodal only relapse after RT were also classified as N+ (as none of 
them received pelvic RT). Finally, 6/317 (1.9%), 10/577 (1.7%), 
39/914 (4.2%) such 'N+' pts were found. Using the Roach formula 
(2/3*PSA + ([Gleason-6] x 10) with a cut-off of>15%, >10% and >5%, the 
individual risk of nodal involvement was calculated. Finally, 3 AI 
classifications method, based on decision trees (the J48 method, the 
Forrest Tree method and the Random Tree method) combined with 3 
techniques of manipulation of imbalanced samples (oversampling, 
undersampling and combined under/ oversampling) were used to 
predict the N status. The accuracy of the Roach formula was 
calculated. 
Results: Table 1 resumes the performances of the Roach formula and 
of the 3 AI methods. All the proposed AI methods taking in account 
more clinical and therapeutic features perform better than the Roach 
formula. Looking at the whole population, the classic approach 
showed an accuracy (i.e. true positives + true negatives/whole 
population) rate ranging, depending on the cut-off, between 34.6% 
and 56.5%. In the same population, the 3 AI methods showed an 
accuracy rates ranging between 76.3% and 98.2%.  
For the low, intermediate and high risk patients, accuracy of the AI 
ranged between 16.7% - 99.4%, 65%-99.5% and 75.6%-98.7%. These 
methods always performed better than the Roach formula. 
The Random Forest method, combined with the Oversampling 
technique is the best method, with specificity, sensibility, and 
accuracy rates of 100%, 96.9% and 98.2%, respectively. 
Conclusions: Roach formula's is suboptimal in predicting the nodal 
status of prostate cancer patients. Non-linear relationships with more 
than two variables probably exist. New approaches taking into 
account more variables could possibly better predict the nodal status 
of the patients. 
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Purpose/Objective: In April 2010 the prospective observational study 
started with the aim of developing predictive models of genito-urinary 
(GU) toxicity and erectile dysfunction for prostate cancer patients 
(pts) treated with high dose radiotherapy (RT) delivered with 
conventional (1.8-2Gy/fr, CONV) or moderately hypo-(2.5-2.7Gy/fr 
HYPO) fractionation. In this ad-interim analysis the correlation 
between dosimetry/clinical factors and the modifications between 
pre-RT(IPSSbasal) and final (IPSSend) IPSS values were investigated. 
Materials and Methods: For all pts several clinical factors were 
collected as: T stage, hormonal therapy, smoking, use of drugs, 
presence of concomitant pathologies, previous surgery, age. Bladder 
parameters were also recovered: volume, D1%, mean dose, DVH and 
Dose Surface Histogram (DSH) in absolute and in relative value, 
referred to both the whole treatment and to the weekly delivered 
treatment (DVHw/DSHw, expected to be more predictive of acute 
symptoms). DSH were calculated using a dedicated software (Vodca, 
MSS Inc.). IPSSend≥15 was considered as end-point. Logistic uni- and 
backward multi-variate (MVA) analyses were performed. Sub-analyses 
were repeated in two selected subgroups: (1) pts with IPSSbasal<15 
(2) pts in the HYPOarm. 
Results: At the time of analysis (November 2012), 212 pts were 
available; full 3D dose-volume data were available for 177/212 (73 
CONV and 104 HYPO). IPSSend≥15 were 56/212 (26%). The dosimetry 
factors more predictive were assessed by looking to the most 
significant differences between DSH/DVH (DVHw/DSHw) of pts with 
IPSSend≥ or <15. Best predictors were the absolute bladder surface 
≥8.5Gy/week and ≥12.5 Gy/week; the correlation was also significant, 
although lower, for absolute DVHw and % DSHw/DVHw. In Fig1 the 
mean DSHw for pts with IPSSend ≥ and <15 are shown (HYPO group). 
The correlation was stronger for the HYPO group. Total DVH/DSH were 
not correlated with IPSSend≥15. At MVA (p<0.0001), the main 
independent predictors of IPSSend≥15 were: baseline IPSS (OR:1.19, 
p<0.001), S12.5w(abs) (OR:1.04, p=0.005); S8.5w(abs) (OR:1.01, 
p=0.13); use of anti-hypertensive (OR:2.08, p=0.058). The predictive 
value of the model was relatively high (AUC=78.2%, CI:71-84%).The 
independent role of S8.5w and S12.5w was confirmed when excluding 
pts with baseline IPSS≥15 (AUC=76.6%) and in the HYPO sub-group 
(AUC=76.2%).  
Fig.1 The average of DSHw for pts with IPSSend ≥ and <15. 
 
  
Conclusions: Absolute weekly DSH/DVH predicts the risk of 
IPSSend≥15 together with basal IPSS and the use of anti-hypertensive. 
The correlation was confirmed if excluding pts with large basal IPSS 
and in the HYPO subgroup. To our knowledge, this result represents 
the first evidence of a dose-volume/surface effect for acute GU 
symptoms prospectively measured in an observational study. The 
inclusion of HYPO pts likely enhanced the effect, due to the 
